Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 4/20 | 0.56 |
| ▸ | RXRA | P19793 | 1/20 | 0.52 |
| ▸ | RXRB | P28702 | 1/20 | 0.52 |
| ▸ | RXRG | P48443 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 4/20 | 0.49 |
| ▸ | USP28 | Q96RU2 | 2/20 | 0.48 |
| ▸ | USP25 | Q9UHP3 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31751182 | 1.00 | SLC6A4 (0.56) | SLC6A4RXRARXRBRXRGCCR5 | |
| SCHEMBL20456269 | 0.94 | SLC6A4 (0.56) | SLC6A4RXRARXRBRXRGCCR5 | |
| SCHEMBL31644088 | 0.85 | SLC6A4 (0.66) | SLC6A4CCR5USP28USP25ALDH1A1 | |
| SCHEMBL368071 | 0.85 | SLC6A4 (0.66) | SLC6A4CCR5USP28USP25ALDH1A1 | |
| SCHEMBL6208609 | 0.83 | RXRA (0.57) | SLC6A4RXRARXRBRXRGRAB9A | |
| SCHEMBL27997579 | 0.82 | RXRA (0.71) | SLC6A4RXRARXRBRXRG | |
| SCHEMBL3726426 | 0.80 | PTGER1 (0.54) | SLC6A4RXRARXRBRXRGCCR5 | |
| SCHEMBL30955958 | 0.80 | PTGER1 (0.54) | SLC6A4RXRARXRBRXRGCCR5 | |
| SCHEMBL30504080 | 0.80 | SLC6A4 (0.59) | SLC6A4CCR5USP28USP25ALDH1A1 | |
| SCHEMBL1447864 | 0.80 | SLC6A4 (0.59) | SLC6A4CCR5USP28USP25ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025262243-A1 | THIENO- AND THIAZOLOPYRIMIDINE-2,6-DIONES AND USE THEREOF AS IMMUNOMODULATORS | INVIOS GMBH (AT) | 2025-12-26 | — | — | WO | disclosed |
| EP-4602044-A1 | SUBSTITUTED 3,7-DIHYDRO-1 H-PURINE-2,6-DIONES AND USE THEREOF | invIOs GmbH (AT) | 2025-08-20 | — | — | EP | disclosed |
| WO-2024133605-A1 | SUBSTITUTED 3,7-DIHYDRO-1 H-PURINE-2,6-DIONES AND USE THEREOF | INVIOS GMBH (AT) | 2024-06-27 | — | — | WO | disclosed |
| EP-4389749-A1 | SUBSTITUTED 3,7-DIHYDRO-1H-PURINE-2,6-DIONES AND USE THEREOF | invIOs GmbH (AT) | 2024-06-26 | — | — | EP | disclosed |
| EP-2435436-B1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBVIE INC (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8354422-B2 | Pyrimidine inhibitors of kinase activity | ABBOTT LABORATORIES INC. (US) | 2013-01-15 | — | — | US | disclosed |
| CN-102459264-A | Pyrimidine inhibitors of kinase activity | ABBOTT LAB | 2012-05-16 | — | — | CN | disclosed |
| WO-2010138576-A1 | PYRIMIDINE INHIBITORS OF KINASE ACTIVITY | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | WO | disclosed |
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | ABBOTT LABORATORIES (US) | 2010-12-02 | — | — | US | disclosed |
| US-7691843-B2 | N-hydroxyamide derivatives possessing antibacterial activity | PFIZER INC. (US) | 2010-04-06 | — | — | US | disclosed |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | VICURON HOLDINGS LLC | 2008-03-06 | — | — | US | disclosed |
| EP-1539744-A4 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARM INC (US) | 2007-06-06 | — | — | EP | disclosed |
| EP-1539744-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | Vicuron Pharmaceuticals, Inc. (US) | 2005-06-15 | — | — | EP | disclosed |
| WO-2004007444-A2 | N-HYDROXYAMIDE DERIVATIVES POSSESSING ANTIBACTERIAL ACTIVITY | VICURON PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100305126-A1 | Pyrimidine Inhibitors of Kinase Activity | IGF1R, CDK2, TK1 | SLC6A4 3899/4885RXRA 2889/4885RXRB 2516/4885 |
| US-20080058304-A1 | N-hydroxyamide derivatives possessing antibacterial activity | AMDHD2, OGA, ENGASE | SLC6A4 2359/4885RXRA 4524/4885RXRB 4684/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.